Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Baylor Research Institute has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 2 distinct examiners and 2 distinct art units.
ZEMAN, ROBERT A is the busiest examiner, with 1 pending action. Application-specific review is appropriate because the pending work is split between separate assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268857 | METHODS FOR DETECTING OR TREATING GLIOBLASTOMA MULTIFORME | BUCHANAN, BAILEY CHEYENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274848 | CHLAMYDIA TRACHOMATIS ANTIGENIC POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES | ZEMAN, ROBERT A | — |
| 18268857 | METHODS FOR DETECTING OR TREATING GLIOBLASTOMA MULTIFORME | BUCHANAN, BAILEY CHEYENNE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18274848 | CHLAMYDIA TRACHOMATIS ANTIGENIC POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES | ZEMAN, ROBERT A | 1645 | §112 | Final Rejection | — | Pending | Jul 28, 2023 |
| 18268857 | METHODS FOR DETECTING OR TREATING GLIOBLASTOMA MULTIFORME | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§103 | Final Rejection | — | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBaylor Research Institute has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert A Zeman has the most, with 1 of Baylor Research Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
